01—Abstract
Summary
Summary of the 8-K filed December 21, 2020. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. announced a significant development on December 21, 2020, via an 8-K filing.
The company reported that the United States Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) for its COVID-19 vaccine, previously known as mRNA-1273. This authorization permits the immediate distribution of the vaccine within the United States.
The granting of the EUA is a pivotal moment for Moderna, enabling the company to commence deliveries of its vaccine to the U.S. government under an existing agreement. This marks a crucial step in the company's efforts to combat the COVID-19 pandemic and represents a major commercial milestone, validating its mRNA technology and its manufacturing capabilities.
02—Key points
Key Highlights
- FDA granted Emergency Use Authorization (EUA) for Moderna's COVID-19 Vaccine (mRNA-1273) on December 18, 2020.
- The EUA allows for the distribution of the vaccine in the United States.
- Moderna has commenced delivery of the vaccine to the U.S. government.
- Deliveries are being made under the agreement dated August 11, 2020, with the U.S. Army Contracting Command.
- The press release announcing the EUA was issued on December 18, 2020, and is attached as an exhibit.
- This event signifies a major commercial and public health milestone for Moderna.
03—Questions
Frequently Asked Questions
What is the main news from this filing?
The main news is that the U.S. Food and Drug Administration (FDA) has granted an Emergency Use Authorization (EUA) for Moderna's COVID-19 vaccine, allowing its distribution in the United States.
When did the EUA become effective?
The EUA was granted on December 18, 2020, and the press release detailing this was issued on the same date. The 8-K filing was made on December 21, 2020, to report this development.
What is Moderna's immediate next step after receiving the EUA?
Moderna has commenced the delivery of its COVID-19 vaccine to the U.S. government, as per their existing agreement.
What is the significance of the agreement mentioned?
The agreement, dated August 11, 2020, is with the Army Contracting Command of the U.S. Department of Defense, outlining the terms for supplying the vaccine to the U.S. government. The EUA allows Moderna to fulfill its obligations under this agreement.
04—Continue